News & Investors

News & Investors

Arrien Pharmaceuticals is a biopharmaceutical company innovating the development of highly selective targeted medicines for cancer patients.

Our pipeline focuses on cancers that are uniquely dependent on the single target driven abnormalities, such that a selective agent has the potential to treat the cancer with dramatic effect. We believe that the most selective medicines have the highest probability of maximally inhibiting the intended target, thereby delivering first or best-in-class agents to control disease and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory expertise to deliver new cancer therapies to patients as quickly and efficiently as possible.